Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Nico van Zandwijk Head of the Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands Former secretary and chairman of the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group Member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC) Member of the Advisory Board of the Thoracic Section of the French National Cancer Institute (INCa) Is the co-author of more than 180 peer- reviewed international papers and chapters Will take up the post of inaugural director of a new thoracic oncology institute at the University of Sydney, Australia, in March 2008 Netherlands Cancer Institute Challenges for the first- and second-line treatment of non-small cell lung cancer Nico van Zandwijk Netherlands Cancer Institute Amsterdam, The Netherlands Thursday 7 February 2008 Agenda 14.10 Chair’s opening Nico van Zandwijk 14.15 The new kid on the block: bevacizumab in first-line NSCLC Nick Thatcher 14.45 First choice in second line: erlotinib in NSCLC Romàn Pérez-Soler 15.15 Discussion 15.30 Coffee break 16.00 Meet the Expert sessions Lung cancer is the most common form of cancer in the world Lung 1,352,100 1,151,300 Breast Bowel 1,023,200 933,900 Stomach 679,000 Prostate Liver 626,200 493,200 Cervix Oesophagus Bladder Non-Hodgkin’s lymphoma 462,100 356,600 300,600 Leukaemia Oral cavity 300,500 274,300 Pancreas Kidney 208,500 Ovary 204,500 Uterus 198,800 Brain and CNS Melanoma Larynx Thyroid 232,300 189,500 160,200 159,000 141,000 Ferlay J, et al. Globocan 2002: Cancer incidence, mortality and prevalence worldwide Lung cancer has high incidence and mortality 250,000 Incidence Estimated new cases/ deaths in the USA (per year) Mortality 213,380 200,000 180,510 160,390 150,000 112,340 100,000 52,180 50,000 40,910 51,190 37,170 33,370 12,890 0 Breast Colon Pancreas Kidney Lung American Cancer Society: cancer facts and figures 2007 Advanced NSCLC: what are the treatment goals for patients? ‘Longer life’ – improved overall survival ‘Better life’ – agents for patients who are not suitable for chemotherapy – improvement of disease-related symptoms – better-tolerated regimens; reduced toxicity – prolonged time to disease progression – improved disease control rate – improved quality of life NSCLC = non-small cell lung cancer NSCLC: what are the challenges that we face in the next decade? Determine how new agents can be best used in conjunction with current treatment modalities Determine how best to tailor therapy for the patient Expanding therapeutic options without increased toxicity for elderly and performance status 2 patients Expanding the eligible patient population for novel targeted agents Treatment options beyond second line